Physician profile
Eric B Vanausdal
NPI 1255826681
$699.11
in general payments reported to CMS, 2019-2025
9 companies · $69.44 in 2025
The $69.44 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $70.13 · 2021: $72.44 · 2022: $81.52 · 2023: $64.11 · 2024: $178 · 2025: $69.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $218.97 | 2019-2025 | Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $133.73 | 2022-2025 | Infuse, Miebo, Biotrue |
| Johnson & Johnson Vision Care, INC. | $109.85 | 2019-2021 | |
| Coopervision INC. | $83.79 | 2022-2024 | Myday Contact Lens, Biofinity Contact Lens |
| Sun Pharmaceutical Industries INC. | $46.41 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.37 | 2019-2021 | |
| Visioneering Technologies, INC. | $28.98 | 2019 | |
| Abbvie INC. | $23.88 | 2022 | |
| Allergan, INC. | $16.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vanausdal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.